These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 26098893)

  • 21. Induction of Potent Neutralizing Antibody Responses by a Designed Protein Nanoparticle Vaccine for Respiratory Syncytial Virus.
    Marcandalli J; Fiala B; Ols S; Perotti M; de van der Schueren W; Snijder J; Hodge E; Benhaim M; Ravichandran R; Carter L; Sheffler W; Brunner L; Lawrenz M; Dubois P; Lanzavecchia A; Sallusto F; Lee KK; Veesler D; Correnti CE; Stewart LJ; Baker D; Loré K; Perez L; King NP
    Cell; 2019 Mar; 176(6):1420-1431.e17. PubMed ID: 30849373
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus.
    McLellan JS; Chen M; Joyce MG; Sastry M; Stewart-Jones GB; Yang Y; Zhang B; Chen L; Srivatsan S; Zheng A; Zhou T; Graepel KW; Kumar A; Moin S; Boyington JC; Chuang GY; Soto C; Baxa U; Bakker AQ; Spits H; Beaumont T; Zheng Z; Xia N; Ko SY; Todd JP; Rao S; Graham BS; Kwong PD
    Science; 2013 Nov; 342(6158):592-8. PubMed ID: 24179220
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Structural basis for immunization with postfusion respiratory syncytial virus fusion F glycoprotein (RSV F) to elicit high neutralizing antibody titers.
    Swanson KA; Settembre EC; Shaw CA; Dey AK; Rappuoli R; Mandl CW; Dormitzer PR; Carfi A
    Proc Natl Acad Sci U S A; 2011 Jun; 108(23):9619-24. PubMed ID: 21586636
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunogenicity of recombinant measles vaccine expressing fusion protein of respiratory syncytial virus in cynomolgus monkeys.
    Sawada A; Yunomae K; Nakayama T
    Microbiol Immunol; 2018 Feb; 62(2):132-136. PubMed ID: 29194753
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of Previous Respiratory Syncytial Virus Infection on Murine Immune Responses to F and G Protein-Containing Virus-Like Particles.
    McGinnes Cullen L; Schmidt MR; Morrison TG
    J Virol; 2019 May; 93(9):. PubMed ID: 30760576
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Vaccination with prefusion-stabilized respiratory syncytial virus fusion protein induces genetically and antigenically diverse antibody responses.
    Mukhamedova M; Wrapp D; Shen CH; Gilman MSA; Ruckwardt TJ; Schramm CA; Ault L; Chang L; Derrien-Colemyn A; Lucas SAM; Ransier A; Darko S; Phung E; Wang L; Zhang Y; Rush SA; Madan B; Stewart-Jones GBE; Costner PJ; Holman LA; Hickman SP; Berkowitz NM; Doria-Rose NA; Morabito KM; DeKosky BJ; Gaudinski MR; Chen GL; Crank MC; Misasi J; Sullivan NJ; Douek DC; Kwong PD; Graham BS; McLellan JS; Mascola JR
    Immunity; 2021 Apr; 54(4):769-780.e6. PubMed ID: 33823129
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Protection against respiratory syncytial virus by inactivated influenza virus carrying a fusion protein neutralizing epitope in a chimeric hemagglutinin.
    Lee YN; Hwang HS; Kim MC; Lee YT; Kim YJ; Lee FE; Kang SM
    Nanomedicine; 2016 Apr; 12(3):759-770. PubMed ID: 26656630
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intranasal immunization with W 80 5EC adjuvanted recombinant RSV rF-ptn enhances clearance of respiratory syncytial virus in a mouse model.
    Passmore C; Makidon PE; O'Konek JJ; Zahn JA; Pannu J; Hamouda T; Bitko V; Myc A; Lukacs NW; Fattom A; Baker JR
    Hum Vaccin Immunother; 2014; 10(3):615-22. PubMed ID: 24326268
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Respiratory syncytial virus prefusogenic fusion (F) protein nanoparticle vaccine: Structure, antigenic profile, immunogenicity, and protection.
    Patel N; Massare MJ; Tian JH; Guebre-Xabier M; Lu H; Zhou H; Maynard E; Scott D; Ellingsworth L; Glenn G; Smith G
    Vaccine; 2019 Sep; 37(41):6112-6124. PubMed ID: 31416644
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Packaging and Prefusion Stabilization Separately and Additively Increase the Quantity and Quality of Respiratory Syncytial Virus (RSV)-Neutralizing Antibodies Induced by an RSV Fusion Protein Expressed by a Parainfluenza Virus Vector.
    Liang B; Ngwuta JO; Herbert R; Swerczek J; Dorward DW; Amaro-Carambot E; Mackow N; Kabatova B; Lingemann M; Surman S; Yang L; Chen M; Moin SM; Kumar A; McLellan JS; Kwong PD; Graham BS; Schaap-Nutt A; Collins PL; Munir S
    J Virol; 2016 Nov; 90(21):10022-10038. PubMed ID: 27581977
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A novel respiratory syncytial virus (RSV) F subunit vaccine adjuvanted with GLA-SE elicits robust protective TH1-type humoral and cellular immunity in rodent models.
    Lambert SL; Aslam S; Stillman E; MacPhail M; Nelson C; Ro B; Sweetwood R; Lei YM; Woo JC; Tang RS
    PLoS One; 2015; 10(3):e0119509. PubMed ID: 25793508
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Parainfluenza Virus 5 Expressing Wild-Type or Prefusion Respiratory Syncytial Virus (RSV) Fusion Protein Protects Mice and Cotton Rats from RSV Challenge.
    Phan SI; Zengel JR; Wei H; Li Z; Wang D; He B
    J Virol; 2017 Oct; 91(19):. PubMed ID: 28747496
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Protective efficacy and immunogenicity of an adenoviral vector vaccine encoding the codon-optimized F protein of respiratory syncytial virus.
    Kohlmann R; Schwannecke S; Tippler B; Ternette N; Temchura VV; Tenbusch M; Uberla K; Grunwald T
    J Virol; 2009 Dec; 83(23):12601-10. PubMed ID: 19776123
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunization with Low Doses of Recombinant Postfusion or Prefusion Respiratory Syncytial Virus F Primes for Vaccine-Enhanced Disease in the Cotton Rat Model Independently of the Presence of a Th1-Biasing (GLA-SE) or Th2-Biasing (Alum) Adjuvant.
    Schneider-Ohrum K; Cayatte C; Bennett AS; Rajani GM; McTamney P; Nacel K; Hostetler L; Cheng L; Ren K; O'Day T; Prince GA; McCarthy MP
    J Virol; 2017 Apr; 91(8):. PubMed ID: 28148790
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Murine Pneumonia Virus Expressing the Fusion Glycoprotein of Human Respiratory Syncytial Virus from an Added Gene Is Highly Attenuated and Immunogenic in Rhesus Macaques.
    Brock LG; Liu X; Liang B; Lingemann M; Liu X; Herbert R; Hackenberg AD; Buchholz UJ; Collins PL; Munir S
    J Virol; 2018 Sep; 92(17):. PubMed ID: 29925656
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Recombinant influenza virus expressing a fusion protein neutralizing epitope of respiratory syncytial virus (RSV) confers protection without vaccine-enhanced RSV disease.
    Lee YN; Hwang HS; Kim MC; Lee YT; Lee JS; Moore ML; Kang SM
    Antiviral Res; 2015 Mar; 115():1-8. PubMed ID: 25513755
    [TBL] [Abstract][Full Text] [Related]  

  • 37. VLPs generated by the fusion of RSV-F or hMPV-F glycoprotein to HIV-Gag show improved immunogenicity and neutralizing response in mice.
    Trinité B; Durr E; Pons-Grífols A; O'Donnell G; Aguilar-Gurrieri C; Rodriguez S; Urrea V; Tarrés F; Mane J; Ortiz R; Rovirosa C; Carrillo J; Clotet B; Zhang L; Blanco J
    Vaccine; 2024 May; 42(15):3474-3485. PubMed ID: 38641492
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Chimeric bovine/human parainfluenza virus type 3 expressing respiratory syncytial virus (RSV) F glycoprotein: effect of insert position on expression, replication, immunogenicity, stability, and protection against RSV infection.
    Liang B; Munir S; Amaro-Carambot E; Surman S; Mackow N; Yang L; Buchholz UJ; Collins PL; Schaap-Nutt A
    J Virol; 2014 Apr; 88(8):4237-50. PubMed ID: 24478424
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Virus-Like Particle Vaccine Containing the F Protein of Respiratory Syncytial Virus Confers Protection without Pulmonary Disease by Modulating Specific Subsets of Dendritic Cells and Effector T Cells.
    Kim KH; Lee YT; Hwang HS; Kwon YM; Kim MC; Ko EJ; Lee JS; Lee Y; Kang SM
    J Virol; 2015 Nov; 89(22):11692-705. PubMed ID: 26355098
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Recombinant bovine/human parainfluenza virus type 3 (B/HPIV3) expressing the respiratory syncytial virus (RSV) G and F proteins can be used to achieve simultaneous mucosal immunization against RSV and HPIV3.
    Schmidt AC; McAuliffe JM; Murphy BR; Collins PL
    J Virol; 2001 May; 75(10):4594-603. PubMed ID: 11312329
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.